MedTrace Logo

A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

NCT06615921 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 265

Last updated 2025-08-08

No results posted yet for this study

Summary

The main aim of this study is to check how effective the treatment with Maribavir has been to remove the CMV viruses from the blood of an adult person with CMV infection after a transplant. Other aims are to learn more about how maribavir is used in normal clinical routine, study the profiles of adults treated with maribavir, and what other treatments have been given, and describe healthcare resources used for CMV management.

Only data already available in the medical records of the participants will be reviewed and collected during this study.

Conditions

  • Cytomegalovirus (CMV)

Interventions

OTHER

No Intervention

This is a non-interventional study.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-14
Primary Completion
2025-07-04
Completion
2025-07-04

Countries

  • Austria
  • Denmark
  • France
  • Germany
  • Italy
  • Netherlands
  • Serbia
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06615921 on ClinicalTrials.gov